ECSP055528A - Composicion farmaceutica que tiene una distribución y potencia uniforme de farmaco - Google Patents

Composicion farmaceutica que tiene una distribución y potencia uniforme de farmaco

Info

Publication number
ECSP055528A
ECSP055528A EC2005005528A ECSP055528A ECSP055528A EC SP055528 A ECSP055528 A EC SP055528A EC 2005005528 A EC2005005528 A EC 2005005528A EC SP055528 A ECSP055528 A EC SP055528A EC SP055528 A ECSP055528 A EC SP055528A
Authority
EC
Ecuador
Prior art keywords
uniform distribution
farmaco
power
pharmaceutical composition
active ingredient
Prior art date
Application number
EC2005005528A
Other languages
English (en)
Inventor
Daniel Scott Gierer
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of ECSP055528A publication Critical patent/ECSP055528A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se describen composiciones farmacéuticas que poseen una distribución y potencia de fármaco uniforme, que utilizan lasofoxifeno como ingrediente activo, y que contienen un dióxido de silicio para reducir la pérdida de ingrediente activo durante el proceso de fabricación, y métodos para fabricar estas composiciones.
EC2005005528A 2002-07-10 2005-01-10 Composicion farmaceutica que tiene una distribución y potencia uniforme de farmaco ECSP055528A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US39509002P 2002-07-10 2002-07-10

Publications (1)

Publication Number Publication Date
ECSP055528A true ECSP055528A (es) 2005-03-10

Family

ID=30115812

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2005005528A ECSP055528A (es) 2002-07-10 2005-01-10 Composicion farmaceutica que tiene una distribución y potencia uniforme de farmaco

Country Status (35)

Country Link
US (2) US20040057992A1 (es)
EP (1) EP1534248B1 (es)
JP (2) JP4446446B2 (es)
KR (1) KR100782693B1 (es)
CN (1) CN100344278C (es)
AP (1) AP2005003201A0 (es)
AR (1) AR040434A1 (es)
AT (1) ATE550017T1 (es)
AU (1) AU2003247017B2 (es)
BR (1) BR0312563A (es)
CA (1) CA2489407C (es)
CY (1) CY1112892T1 (es)
DK (1) DK1534248T3 (es)
EA (1) EA007268B1 (es)
EC (1) ECSP055528A (es)
ES (1) ES2395123T3 (es)
HN (1) HN2003000206A (es)
HR (1) HRP20041196A2 (es)
IL (2) IL165746A0 (es)
IS (1) IS7594A (es)
MA (1) MA27318A1 (es)
MX (1) MXPA05000394A (es)
NO (1) NO20050018L (es)
NZ (1) NZ537278A (es)
OA (1) OA12883A (es)
PA (1) PA8576201A1 (es)
PE (1) PE20040104A1 (es)
PL (1) PL374913A1 (es)
PT (1) PT1534248E (es)
SI (1) SI1534248T1 (es)
TN (1) TNSN05006A1 (es)
TW (1) TW200406222A (es)
UY (1) UY27886A1 (es)
WO (1) WO2004006895A1 (es)
ZA (1) ZA200410196B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PA8576201A1 (es) * 2002-07-10 2004-05-26 Pfizer Prod Inc Composicion farmaceutica que tiene una distribucion y potencia uniforme de farmaco
US20040253305A1 (en) * 2003-06-12 2004-12-16 Luner Paul E. Pharmaceutical compositions of atorvastatin
US20050271717A1 (en) * 2003-06-12 2005-12-08 Alfred Berchielli Pharmaceutical compositions of atorvastatin
EP1871359A1 (en) * 2005-04-07 2008-01-02 Miso Sabovic Delaying the ageing process and disorders caused by ageing
CA2607419C (en) * 2005-04-26 2014-06-17 Dainippon Sumitomo Pharma Co., Ltd. Granular preparation containing biguanide compound
GB0516604D0 (en) * 2005-08-12 2005-09-21 Sandoz Ag Rapidly dispersing/disintegrating compositions
EP1948179A1 (en) 2005-11-11 2008-07-30 Boehringer Ingelheim International GmbH Quinazoline derivatives for the treatment of cancer diseases
EP4403221A3 (en) 2007-02-23 2024-10-09 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics
CA2587805C (en) * 2007-04-25 2014-02-18 The Procter & Gamble Company Improved vitamin d content uniformity in pharmaceutical dosage forms
CN101820863A (zh) * 2007-10-10 2010-09-01 马林克罗特贝克公司 直接可压制的高功能性颗粒状微晶纤维素基赋形剂、其制备方法和用途
US20100055180A1 (en) * 2007-10-10 2010-03-04 Mallinckrodt Baker, Inc. Directly Compressible Granular Microcrystalline Cellulose Based Excipient, Manufacturing Process and Use Thereof
US20090274757A1 (en) * 2008-05-01 2009-11-05 Wyeth Pharmaceutical polish formulations
CN103479584A (zh) 2008-05-02 2014-01-01 吉里德科学公司 固体载体颗粒在改善药物制剂加工性中的应用
PL2451445T3 (pl) 2009-07-06 2019-09-30 Boehringer Ingelheim International Gmbh Sposób suszenia BIBW2992, jego soli i stałych preparatów farmaceutycznych zawierających tę substancję czynną
SG11201401583YA (en) * 2011-10-17 2014-09-26 Lexicon Pharmaceuticals Inc Solid dosage forms of (s)-ethyl 2-amino-3-(4-(2-amino-6-((r)-1-(4-chloro-2-(3-methyl-1h-pyrazol-1-yl)phenyl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)phenyl)propanoate
CA2873961C (en) 2012-05-14 2017-09-26 Shionogi & Co., Ltd. Preparation containing 6,7-unsaturated-7-carbamoyl morphinan derivatives
WO2015036512A1 (en) * 2013-09-13 2015-03-19 Bayer Pharma Aktiengesellschaft Pharmaceutical compositions containing refametinib
RU2539375C1 (ru) * 2013-11-07 2015-01-20 Общество С Ограниченной Ответственностью "Валента-Интеллект" Фармацевтическая композиция в форме таблетки и способ ее получения
US9242965B2 (en) 2013-12-31 2016-01-26 Boehringer Ingelheim International Gmbh Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
CN103830196A (zh) * 2014-03-14 2014-06-04 王志刚 一种酒石酸拉索昔芬分散片及其制备方法
TWI535784B (zh) 2014-08-26 2016-06-01 財團法人工業技術研究院 剪切增稠配方、及包含其之複合材料
CN105434444B (zh) * 2014-09-29 2021-02-05 上海奥奇医药科技有限公司 一种A-失碳-5α雄甾烷化合物的口服制剂
CN109789095A (zh) * 2016-07-25 2019-05-21 Ebbu 公司 新的大麻片剂配方和组合物及其制造方法
NZ752443A (en) 2016-10-11 2022-11-25 Univ Duke Lasofoxifene treatment of er+ breast cancer
CN117771239A (zh) 2018-04-10 2024-03-29 杜克大学 乳腺癌的拉索昔芬治疗
GB202116903D0 (en) 2021-11-18 2022-01-05 Sermonix Pharmaceuticals Inc Lasofoxifene treatment of aromatase-resistant er+ cancer
CN114288258A (zh) * 2022-02-18 2022-04-08 山东新时代药业有限公司 一种单硝酸异山梨酯片及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4182A (en) * 1845-09-09 Island
US4880636A (en) * 1988-05-13 1989-11-14 Franz Robert M Film coated tablet of ranitidine HCl
US5552412A (en) 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
UA51676C2 (uk) 1995-11-02 2002-12-16 Пфайзер Інк. (-)цис-6(s)-феніл-5(r)[4-(2-піролідин-1-ілетокси)феніл]-5,6,7,8-тетрагідронафталін-2-ол d-тартрат, спосіб його одержання, спосіб лікування захворювань, що піддаються лікуванню агоністами естрогену, та фармацевтична композиція
TW442286B (en) * 1996-02-28 2001-06-23 Pfizer New therapeutic uses of estrogen agonists
US6372457B1 (en) 1997-01-14 2002-04-16 Arkion Life Sciences Llc Process and materials for production of glucosamine
KR200161927Y1 (ko) * 1997-08-26 1999-12-01 윤종용 냉장고
YU26700A (sh) 1999-05-24 2002-06-19 Pfizer Products Inc. Postupak za cis-1-(2-(4-(6-metoksi-2-fenil-1,2,3,4- tetrahidronaftalen-1-il)fenoksi)etil)pirolidin
US6436977B1 (en) * 1999-09-29 2002-08-20 Pfizer Inc. Dosing regimens for lasofoxifene
US6419956B1 (en) * 1999-12-30 2002-07-16 Ancile Pharmaceuticals Odor-masking coating for a pharmaceutical preparation
EP1145719A3 (en) * 2000-03-10 2001-11-14 Pfizer Products Inc. Use a ferrous salt for inhibiting oxidative degradation of pharmaceutical formulations
AR029538A1 (es) * 2000-07-06 2003-07-02 Wyeth Corp Composiciones farmaceuticas de agentes estrogenicos
IL158390A0 (en) * 2001-05-01 2004-05-12 Pfizer Prod Inc Method for manufacturing a low dose pharmaceutical composition
PA8576201A1 (es) * 2002-07-10 2004-05-26 Pfizer Prod Inc Composicion farmaceutica que tiene una distribucion y potencia uniforme de farmaco

Also Published As

Publication number Publication date
AU2003247017B2 (en) 2008-03-06
PA8576201A1 (es) 2004-05-26
JP2007031451A (ja) 2007-02-08
CN100344278C (zh) 2007-10-24
IL165746A0 (en) 2006-01-15
EA200401583A1 (ru) 2005-06-30
CN1668285A (zh) 2005-09-14
DK1534248T3 (da) 2012-06-25
ES2395123T3 (es) 2013-02-08
OA12883A (en) 2006-09-15
IL165746A (en) 2008-12-29
BR0312563A (pt) 2005-04-19
TNSN05006A1 (fr) 2007-05-14
CA2489407C (en) 2009-01-27
JP4446446B2 (ja) 2010-04-07
HK1077747A1 (en) 2006-02-24
PL374913A1 (en) 2005-11-14
SI1534248T1 (sl) 2012-07-31
HRP20041196A2 (en) 2005-04-30
EP1534248A1 (en) 2005-06-01
AP2005003201A0 (en) 2005-03-31
WO2004006895A1 (en) 2004-01-22
CA2489407A1 (en) 2004-01-22
PT1534248E (pt) 2012-05-25
JP2005535671A (ja) 2005-11-24
US20070110800A1 (en) 2007-05-17
EP1534248B1 (en) 2012-03-21
TW200406222A (en) 2004-05-01
KR100782693B1 (ko) 2007-12-07
AR040434A1 (es) 2005-04-06
KR20050017102A (ko) 2005-02-21
US7553500B2 (en) 2009-06-30
US20040057992A1 (en) 2004-03-25
MXPA05000394A (es) 2005-03-23
NO20050018L (no) 2005-01-12
ATE550017T1 (de) 2012-04-15
UY27886A1 (es) 2004-02-27
NZ537278A (en) 2007-07-27
HN2003000206A (es) 2004-07-27
EA007268B1 (ru) 2006-08-25
CY1112892T1 (el) 2016-04-13
MA27318A1 (fr) 2005-05-02
AU2003247017A1 (en) 2004-02-02
ZA200410196B (en) 2006-07-26
PE20040104A1 (es) 2004-02-27
IS7594A (is) 2004-12-13

Similar Documents

Publication Publication Date Title
UY27886A1 (es) Composicion farmaceutica que tiene una distribucion y potencia uniforme de farmaco.
ES2525410T3 (es) Composiciones y métodos para el tratamiento de enfermedades hiperproliferativas dérmicas
HN2004000232A (es) " derivados de pirrolo(3,4-c) pirazol activos como inhibidores de quinasa, proceso para su preparacion y composiciones farmaceuticas que los comprenden."
PY0206703A (es) Metodo para fabricar una composicion farmaceutica de dosis baja que tiene una distribucion y potencia del farmaco uniformes
EA200701065A1 (ru) Инъецируемые составы, содержащие нанодисперсный оланзапин
NO20062504L (no) Sammensetninger og doseringsformer for forbedret absorpsjon
CR8266A (es) Derivados de pirimidina para el tratamiento del crecimiento celular anormal
CL2011000170A1 (es) Composicion farmaceutica solida y estabilizada que comprende un ingrediente farmaceuticamente activo, oxido de titanio y un plastificante; procedimiento para estabilizar la composicion farmaceutica durante una irradiacion luminosa.
DK1487461T3 (da) Fremgangsmåder til anvendelse af og præparater omfattende immunomodulatoriske forbindelser til behandling og håndtering af myelodysplastiske syndromer
GT199900203A (es) Composiciones de celecoxib.
MXPA05012573A (es) Derivados de pirazolo-quinazolina, procedimiento para su preparacion y su uso como inhibidores de cinasa.
NO20076613L (no) Farmasoytiske formuleringer og anvendelse derav
DK1299348T3 (da) Forbindelser og sammensætninger til levering af aktive midler
BR0306870A (pt) Composição farmacêutica oral, e, método para preparar a mesma
ECSP055726A (es) Composición farmacéutica estabilizada que contiene excipientes básicos
TW200716628A (en) Novel compounds
SE9900961D0 (sv) Novel compounds
PA8599701A1 (es) Formas de dosificacion y procedimientos de tratamiento que usan inhibidores del vegfr
UA86776C2 (ru) Производные бензимидазола, фармацевтическая композиция, которая их содержит, способ их получения и применение
AR033293A1 (es) Composiciones y metodos para aumentar la biodisponibilidad de agentes farmaceuticos
MXPA05014184A (es) Utilizacion de acido hialuronico para la preparacion de composiciones para el tratamiento de aftas en la cavidad oral.
GT200500113A (es) Derivados de pirimidina para tratar el crecimiento celular anomalo
MX2009008813A (es) Composicion farmaceutica que contiene floroglucinol y paracetamol.
DOP2003000655A (es) Composicion farmaceutica que tiene una distribucion y potencia uniforme de farmaco
BRPI0507985A (pt) derivados de piperazina uréia para o tratamento de endometriose